C J M Melief
Overview
Explore the profile of C J M Melief including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Meir H, Nout R, Welters M, Loof N, Kam M, van Ham J, et al.
Oncoimmunology
. 2017 Mar;
6(2):e1267095.
PMID: 28344877
New treatments based on combinations of standard therapeutic modalities and immunotherapy are of potential use, but require a profound understanding of immune modulatory properties of standard therapies. Here, the impact...
2.
Britten C, Janetzki S, Butterfield L, Ferrari G, Gouttefangeas C, Huber C, et al.
Immunity
. 2012 Jul;
37(1):1-2.
PMID: 22840835
No abstract available.
3.
van Monsjou H, van Velthuysen M, van den Brekel M, Jordanova E, Melief C, Balm A
Int J Cancer
. 2011 May;
130(8):1806-12.
PMID: 21607949
The role of human papillomavirus (HPV) in head and neck squamous cell carcinoma (HNSCC) development has been recognized only in the last decade. Although younger patients develop HNSCC associated with...
4.
Britten C, Janetzki S, van der Burg S, Huber C, Kalos M, Levitsky H, et al.
Cancer Immunol Immunother
. 2010 Nov;
60(1):15-22.
PMID: 21080166
Many assays to evaluate the nature, breadth, and quality of antigen-specific T cell responses are currently applied in human medicine. In most cases, assay-related protocols are developed on an individual...
5.
Kessler J, Melief C
Leukemia
. 2007 Jul;
21(9):1859-74.
PMID: 17611570
The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted...
6.
Kessler J, Bres-Vloemans S, van Veelen P, de Ru A, Huijbers I, Camps M, et al.
Leukemia
. 2006 Aug;
20(10):1738-50.
PMID: 16932347
For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte...
7.
Vambutas A, DeVoti J, Nouri M, Drijfhout J, Lipford G, Bonagura V, et al.
Vaccine
. 2005 Aug;
23(45):5271-80.
PMID: 16054734
This study was performed to test the therapeutic efficacy of overlapping long E6 and E7 peptides, containing both CD4+ T-helper and CD8+ CTL epitopes, on CRPV-induced lesions, which is an...
8.
Dadabayev A, Sandel M, Menon A, Morreau H, Melief C, Offringa R, et al.
Cancer Immunol Immunother
. 2004 Jun;
53(11):978-86.
PMID: 15197496
Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a key role in a cellular antitumor immune response. In this study we investigated the exact localization of DCs...
9.
Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1
Ossevoort M, Visser B, van den Wollenberg D, van der Voort E, Offringa R, Melief C, et al.
Gene Ther
. 2003 Oct;
10(24):2020-8.
PMID: 14566361
A major obstacle in gene-therapy protocols is T-cell-mediated destruction of transgene-expressing cells. Therefore new approaches are needed to prevent rapid clearance of transduced cells. We exploited the Gly-Ala repeat (GAr)...
10.
Offringa R, De Jong A, Toes R, van der Burg S, Melief C
Curr Top Microbiol Immunol
. 2003 Jun;
276:215-40.
PMID: 12797450
The design of the human papillomavirus (HPV) infection cycle is tightly fitted to the differentiation program of its natural host, the keratinocyte. This has important consequences for the role of...